AvalehtGSK • NYSE
add
GSK plc
Viimane sulgemishind
39,62 $
Tänane vahemik
39,81 $ - 40,55 $
Aasta vahemik
31,72 $ - 44,67 $
Turuväärtus
80,73 mld USD
Keskmine maht
5,14 mln
P/E suhe
17,92
Dividendimäär
4,11%
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (GBP) | juuni 2025info | Y/Y muutus |
|---|---|---|
Käive | 7,99 mld | 1,29% |
Põhitegevusega seonduv kulu | 3,39 mld | −3,34% |
Puhastulu | 1,44 mld | 23,02% |
Puhaskasumimarginaal | 18,07 | 21,44% |
Puhaskasum aktsia kohta | 1,24 | 185,82% |
EBITDA | 3,60 mld | 21,53% |
Tõhus maksumäär | 12,77% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (GBP) | juuni 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 3,62 mld | 21,32% |
Kogu vara | 59,26 mld | 2,05% |
Kõik kohustused | 44,90 mld | 1,37% |
Kogu omakapital | 14,35 mld | — |
Emiteeritud aktsiate arv | 4,05 mld | — |
Hinna ja väärtuse suhe P/B | 10,85 | — |
Varade tasuvus | 10,16% | — |
Kapitali tasuvus | 19,10% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (GBP) | juuni 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 1,44 mld | 23,02% |
Põhitegevuse rahakäive | 2,10 mld | 88,32% |
Investeeringute raha | −625,00 mln | −181,17% |
Finantseerimise raha | −2,37 mld | −49,75% |
Raha ja raha ekvivalentide muutus | −927,00 mln | −418,56% |
Tasuta rahavoog | 935,12 mln | 51,50% |
Teave
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine. Wikipedia
Tegevjuht
Asutatud
27. dets 2000
Veebisait
Töötajate arv
68 629
